Cost Effectiveness

For U.S. patients with acute ischemic stroke, late mechanical thrombectomy combined with standard medical care was found to be a cost-effective option compared with standard care alone, researchers reported.

Recently published results show total shoulder arthroplasty is a cost-effective procedure and, according to quality of health economic studies scores, most cost analysis literature on the subject is high quality.

In a cost-effectiveness model, the PCSK9 inhibitor alirocumab had good economic value at its present cost in patients with a baseline LDL greater than 100 mg/dL, though less value in patients with LDL less than 100 mg/dL.

A cost analysis of findings from the COLCOT trial showed that the addition of low-dose colchicine therapy to standard care after MI resulted in a 69% lifetime cost reduction compared with standard care alone.

Although tafamidis can provide substantial clinical benefit for patients with transthyretin amyloid cardiomyopathy, the drug exceeds cost-effectiveness thresholds at its current list price of $225,000 per year, according to an analysis published in Circulation.

Results of a 5-year estimate showed that up to 20% of CV events could be prevented if patients with ischemic heart disease or MI received additional secondary prevention therapies that they are eligible for.